GLP-1 receptor agonist: Difference between revisions
Content deleted Content added
copyedit |
Added link to DPP-4 inhibitors as they are in the same pathway. |
||
| Line 11: | Line 11: | ||
Under investigation: <ref name=Baggio_2008/> |
Under investigation: <ref name=Baggio_2008/> |
||
* [[taspoglutide]], phase III halted Sept 2010, |
* [[taspoglutide]], phase III halted Sept 2010, |
||
These agents work in the same pathway as [[DPP-4 inhibitors]] but are generally considered more potent.<ref>{{cite web |url=http://www.medscape.com/viewarticle/824247 |title=GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes}}</ref> |
|||
==References== |
==References== |
||
Revision as of 22:25, 13 October 2014
Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes.[1] One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.[2]
There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas.[3]
Licensed GLP-1 agonists:
- exenatide (Byetta/Bydureon), licensed in 2005/2012
- liraglutide (Victoza), licensed 2010[4]
- lixisenatide (Lyxumia), licensed in EU 2013[5]
- albiglutide (Tanzeum), licensed in 2014 by GSK[6]
Under investigation: [1]
- taspoglutide, phase III halted Sept 2010,
These agents work in the same pathway as DPP-4 inhibitors but are generally considered more potent.[7]
References
- ^ a b Baggio LL (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide". Medscape Diabetes & Endocrinology.
- ^ "Standards of medical care in diabetes--2012". Diabetes Care. 35 Suppl 1: S11–63. 2012. doi:10.2337/dc12-s011. PMC 3632172. PMID 22187469.
- ^ Schweizer M, Perencevich E, McDanel J, Carson J, Formanek M, Hafner J, Braun B, Herwaldt L (2013). "Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis". BMJ. 346: f2743. doi:10.1136/bmj.f2743. PMC 3681273. PMID 23766464.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "FDA Approves New Treatment for Type 2 Diabetes".
- ^ "Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA".
- ^ "FDA Approves Weekly Injectable Diabetes Drug: Albiglutide".
- ^ "GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes".
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |